ALLO — Allogene Therapeutics, Inc.

Summary of ALLO Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Cash Position: As of March 31, 2026, ALLO reported $266.9 million in cash, cash equivalents, and investments. A public offering in April raised approximately $200.4 million, extending the cash runway into 2029.
• Expenses: R&D expenses for Q1 were $32 million, including $2.7 million in non-cash stock-based compensation. G&A expenses totaled $14.1 million, with $5.6 million in non-cash stock-based compensation.
• Net Loss: The company reported a net loss of $42.6 million, or $0.18 per share.

2. Strategic Updates and Business Highlights:

• ALPHA-3 Trial: ALLO's lead program, SemiCell, showed promising results in an interim futility analysis, achieving a 58.3% MRD clearance rate compared to 16.7% in the observation arm. This trial aims to improve cure rates for large B cell lymphoma by enabling outpatient treatment.
• ALLO-329 Program: This program is progressing in early clinical development for autoimmune diseases. Initial signs of clinical activity have been observed, and the trial is designed to establish a tolerability profile before escalating doses.
• Global Expansion: ALLO-3 is expanding its trial sites globally, with regulatory approvals in Australia and South Korea, aiming for over 80 sites worldwide.

3. Forward Guidance and Outlook:

• Operating cash expense guidance for 2026 has been increased from approximately $150 million to $165 million, with GAAP operating expenses expected to rise from $210 million to $225 million.
• The company anticipates an interim analysis for EFS in mid-2027 and a primary analysis in mid-2028, with plans to file a BLA based on these results.

4. Challenges and Points of Concern:

• Enrollment and Competition: While there has been robust engagement in the ALPHA-3 trial, the competitive landscape for CAR T therapies in autoimmune diseases poses challenges. The company is closely monitoring patient enrollment and site activation.
• Safety Profile: For ALLO-329, maintaining a favorable safety profile is critical, especially given the complexities of autoimmune diseases. The company is cautious about dose escalation and its potential impact on safety.

5. Notable Q&A Insights:

• Analysts inquired about the initial signs of clinical activity in ALLO-329, with management indicating that they would provide more detailed updates in Q4.
• There was positive feedback from community practices regarding the SemiCell interim data, with increased interest in participation in the ALPHA-3 trial.
• Management emphasized the importance of safety in the ALLO-329 program, indicating that they would continue to escalate doses cautiously while monitoring for adverse effects.
• The interim analysis results for ALPHA-3 have reportedly stimulated increased interest from new trial sites, suggesting a positive shift in engagement since the announcement.

Overall, ALLO is positioned for growth with promising clinical data, a strong cash position, and strategic initiatives aimed at expanding its market presence in both oncology and autoimmune diseases. However, the company must navigate competitive pressures and ensure patient safety as it advances its clinical programs.